Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Tornier majority stake goes to investor group: French orthopedic device maker Tornier is majority owned by private equity investor Warburg Pincus and venture capital firm The Vertical Group under a transaction announced July 18. The Grenoble, France-based company's joint replacement offerings include hips, knees, shoulders, ankles and other extremity prostheses. Terms of the deal were not disclosed. Similarly, orthopedic device firm Encore Medical recently was bought out by private investment firm Blackstone Capital Partners (1"The Gray Sheet" July 10, 2006, p. 9). In conjunction with the Tornier investment deal, President and CEO Alain Tornier steps down to become chairman as Douglas Kohrs takes over as president and CEO. Kohrs served in the same positions at American Medical Systems from 1999 until 2005, and as chairman from 2004 until 2006...

You may also be interested in...



Conor Ramps Up Production Of CoStar Stent To Prep For U.S. Launch

Conor Medsystems is already boosting manufacturing capacity in preparation for the U.S. launch of its CoStar drug-eluting stent, though the product is not slated to hit the market until late next year at the earliest

VeraLight’s Scout Eliminates Fasting From Diabetes Screening

VeraLight expects to support a de novo 510(k) application for its Scout diabetes screening technology with a trial demonstrating the test's superiority to fasting plasma glucose (FPG) screening, according to CEO David Van Avermaete

Hologic Acquires Suros To Expand Its Breast Cancer Detection Offerings

Hologic aims to break into the Johnson & Johnson-dominated breast biopsy market following its acquisition of Suros Surgical Systems

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel